Top Tweets for #CAPItello281
Analysis of the phase III #CAPItello281 trial: Capivasertib + Abiraterone in PTEN-deficient metastatic hormone-sensitive #ProstateCancer. @Daniel_J_George @DukeCancer joins @neerajaiims @huntsmancancer in this conversation on UroToday. Dr. George highlights this as the first study conducted exclusively in PTEN-loss patients, demonstrating that PTEN deficiency defines a fundamentally more aggressive disease biology requiring different treatment approaches than standard #mHSPC. #WatchNow > https://t.co/nmmdY1UQai

We touched on 6 studies (3 from #ASCO26 and 3 recent @FDAOncology ✅) during our GU Malignancies Conference Highlights w/ @Uromigos
⭐️ #PROTEUS
⭐️ #TALAPRO3
⭐️ #EV302
✅ #POTOMAC
✅ #CAPItello281
✅ #LITESPARK022
#OncTwitter #gusm @OncUpdates

GU Malignancies Conference Highlights from #ASCO26 (and recent @US_FDA ✅) w/ @Uromigos
⭐️ #PROTEUS
⭐️ #TALAPRO3
⭐️ #EV302
✅ #POTOMAC
✅ #CAPItello281
✅ #LITESPARK022
Full 🗣️
⭐️ “Oncology Brothers” podcast
⭐️ https://t.co/DOo4V61t61
#OncTwitter @OncUpdates
GU Malignancies Conference Highlights from #ASCO26 (and recent @US_FDA ✅) w/ @Uromigos
⭐️ #PROTEUS
⭐️ #TALAPRO3
⭐️ #EV302
✅ #POTOMAC
✅ #CAPItello281
✅ #LITESPARK022
Full 🗣️
⭐️ “Oncology Brothers” podcast
⭐️ https://t.co/DOo4V61t61
#OncTwitter @OncUpdates
Analysis of the phase III #CAPItello281 trial: Capivasertib + Abiraterone in PTEN-deficient metastatic hormone-sensitive #ProstateCancer. @Daniel_J_George @DukeCancer joins @neerajaiims @huntsmancancer in this conversation on UroToday. Dr. George highlights this as the first study conducted exclusively in PTEN-loss patients, demonstrating that PTEN deficiency defines a fundamentally more aggressive disease biology requiring different treatment approaches than standard metastatic hormone-sensitive prostate cancer. #WatchNow > https://t.co/k6vSbRfZgo

Analysis of the phase III #CAPItello281 trial: Capivasertib + Abiraterone in PTEN-deficient metastatic hormone-sensitive #ProstateCancer. @Daniel_J_George @DukeCancer joins @neerajaiims @huntsmancancer in this conversation on UroToday. Dr. George highlights this as the first study conducted exclusively in PTEN-loss patients, demonstrating that PTEN deficiency defines a fundamentally more aggressive disease biology requiring different treatment approaches than standard metastatic hormone-sensitive prostate cancer. #WatchNow > https://t.co/k6vSbRfZgo

Analysis of the phase III #CAPItello281 trial: Capivasertib + Abiraterone in PTEN-deficient metastatic hormone-sensitive #ProstateCancer. @Daniel_J_George @DukeCancer joins @neerajaiims @huntsmancancer in this conversation on UroToday. Dr. George highlights this as the first study conducted exclusively in PTEN-loss patients, demonstrating that PTEN deficiency defines a fundamentally more aggressive disease biology requiring different treatment approaches than standard #mHSPC. #WatchNow > https://t.co/nmmdY1UQai

Analysis of the phase III #CAPItello281 trial: Capivasertib + Abiraterone in PTEN-deficient metastatic hormone-sensitive #ProstateCancer. @Daniel_J_George @DukeCancer joins @neerajaiims @huntsmancancer in this conversation on UroToday. Dr. George highlights this as the first study conducted exclusively in PTEN-loss patients, demonstrating that PTEN deficiency defines a fundamentally more aggressive disease biology requiring different treatment approaches than standard metastatic hormone-sensitive prostate cancer. #WatchNow > https://t.co/k6vSbRfZgo

Analysis of the phase III #CAPItello281 trial: Capivasertib + Abiraterone in PTEN-deficient metastatic hormone-sensitive #ProstateCancer. @Daniel_J_George @DukeCancer joins @neerajaiims @huntsmancancer in this conversation on UroToday. Dr. George highlights this as the first study conducted exclusively in PTEN-loss patients, demonstrating that PTEN deficiency defines a fundamentally more aggressive disease biology requiring different treatment approaches than standard metastatic hormone-sensitive prostate cancer. #WatchNow > https://t.co/k6vSbRfZgo

Analysis of the phase III #CAPItello281 trial: Capivasertib + Abiraterone in PTEN-deficient metastatic hormone-sensitive #ProstateCancer. @Daniel_J_George @DukeCancer joins @neerajaiims @huntsmancancer in this conversation on UroToday. Dr. George highlights this as the first study conducted exclusively in PTEN-loss patients, demonstrating that PTEN deficiency defines a fundamentally more aggressive disease biology requiring different treatment approaches than standard #mHSPC. #WatchNow > https://t.co/nmmdY1UQai

Analysis of the phase III #CAPItello281 trial: Capivasertib + Abiraterone in PTEN-deficient metastatic hormone-sensitive #ProstateCancer. @Daniel_J_George @DukeCancer joins @neerajaiims @huntsmancancer in this conversation on UroToday. Dr. George highlights this as the first study conducted exclusively in PTEN-loss patients, demonstrating that PTEN deficiency defines a fundamentally more aggressive disease biology requiring different treatment approaches than standard metastatic hormone-sensitive prostate cancer. #WatchNow > https://t.co/k6vSbRfZgo

Analysis of the phase III #CAPItello281 trial: Capivasertib + Abiraterone in PTEN-deficient metastatic hormone-sensitive #ProstateCancer. @Daniel_J_George @DukeCancer joins @neerajaiims @huntsmancancer in this conversation on UroToday. Dr. George highlights this as the first study conducted exclusively in PTEN-loss patients, demonstrating that PTEN deficiency defines a fundamentally more aggressive disease biology requiring different treatment approaches than standard #mHSPC. #WatchNow > https://t.co/nmmdY1UQai

Analysis of the phase III #CAPItello281 trial: Capivasertib + Abiraterone in PTEN-deficient metastatic hormone-sensitive #ProstateCancer. @Daniel_J_George @DukeCancer joins @neerajaiims @huntsmancancer in this conversation on UroToday. Dr. George highlights this as the first study conducted exclusively in PTEN-loss patients, demonstrating that PTEN deficiency defines a fundamentally more aggressive disease biology requiring different treatment approaches than standard metastatic hormone-sensitive prostate cancer. #WatchNow > https://t.co/k6vSbRfZgo

Phase III #CAPItello281 trial results for #mHSPC with PTEN loss. Karim Fizazi, MD @GustaveRoussy joins @neerajaiims @huntsmancancer reviewing CAPItello‑281, where adding capivasertib to abiraterone in PTEN‑deficient mHSPC cut the risk of radiographic progression or death by ~20%, extending median rPFS by 7.5 months and showing the greatest benefit in men with the highest degree of PTEN loss. #WatchNow > https://t.co/o1H3Lhlhly
Analysis of the phase III #CAPItello281 trial: Capivasertib + Abiraterone in PTEN-deficient metastatic hormone-sensitive #ProstateCancer. @Daniel_J_George @DukeCancer joins @neerajaiims @huntsmancancer in this conversation on UroToday. Dr. George highlights this as the first study conducted exclusively in PTEN-loss patients, demonstrating that PTEN deficiency defines a fundamentally more aggressive disease biology requiring different treatment approaches than standard metastatic hormone-sensitive prostate cancer. #WatchNow > https://t.co/k6vSbRfZgo

Analysis of the phase III #CAPItello281 trial: Capivasertib + Abiraterone in PTEN-deficient metastatic hormone-sensitive #ProstateCancer. @Daniel_J_George @DukeCancer joins @neerajaiims @huntsmancancer in this conversation on UroToday. Dr. George highlights this as the first study conducted exclusively in PTEN-loss patients, demonstrating that PTEN deficiency defines a fundamentally more aggressive disease biology requiring different treatment approaches than standard #mHSPC. #WatchNow > https://t.co/nmmdY1UQai

Phase III #CAPItello281 trial results for #mHSPC with PTEN loss. Karim Fizazi, MD @GustaveRoussy joins @neerajaiims @huntsmancancer reviewing CAPItello‑281, where adding capivasertib to abiraterone in PTEN‑deficient mHSPC cut the risk of radiographic progression or death by ~20%, extending median rPFS by 7.5 months and showing the greatest benefit in men with the highest degree of PTEN loss. #WatchNow > https://t.co/o1H3Lhlhly
Analysis of the phase III #CAPItello281 trial: Capivasertib + Abiraterone in PTEN-deficient metastatic hormone-sensitive #ProstateCancer. @Daniel_J_George @DukeCancer joins @neerajaiims @huntsmancancer in this conversation on UroToday. Dr. George highlights this as the first study conducted exclusively in PTEN-loss patients, demonstrating that PTEN deficiency defines a fundamentally more aggressive disease biology requiring different treatment approaches than standard metastatic hormone-sensitive prostate cancer. #WatchNow > https://t.co/k6vSbRfZgo

Phase III #CAPItello281 trial results for #mHSPC with PTEN loss. Karim Fizazi, MD @GustaveRoussy joins @neerajaiims @huntsmancancer reviewing CAPItello‑281, where adding capivasertib to abiraterone in PTEN‑deficient mHSPC cut the risk of radiographic progression or death by ~20%, extending median rPFS by 7.5 months and showing the greatest benefit in men with the highest degree of PTEN loss. #WatchNow > https://t.co/o1H3Lhlhly
Analysis of the phase III #CAPItello281 trial: Capivasertib + Abiraterone in PTEN-deficient metastatic hormone-sensitive #ProstateCancer. @Daniel_J_George @DukeCancer joins @neerajaiims @huntsmancancer in this conversation on UroToday. Dr. George highlights this as the first study conducted exclusively in PTEN-loss patients, demonstrating that PTEN deficiency defines a fundamentally more aggressive disease biology requiring different treatment approaches than standard metastatic hormone-sensitive prostate cancer. #WatchNow > https://t.co/k6vSbRfZgo

💫PCa: Tx Selection, Response, & Monitoring #GU26
👉Dr @Daniel_J_George presents PRO from #CAPITELLO281 comparing #Capivasertib + Abi vs Abi alone in pts with PTEN-deficient mCSPC.
📊 No differences in least mean square change in FACT-P, physical well being, or functional well being
⚠️ However, #Capivasertib + Abi a/w☝️AEs leading to dose reductions/interruptions
- Diarrhea (51% vs 8%)
- Rash (35% vs 7%)
- Hyperglycemia (38% vs 13%)
🔑 Key Takeaways that increased benefits of #Capivasertib must be weighed against early and reversible toxicity. Question if PROs measures are capturing effect of increased tox on QOL.
@TDorffOnc @APCCC_Lugano @neerajaiims @bergsa83 @PBarataMD @Dr_RaviMadan @AarmstrongDuke @ChrisSweens1 @DrRanaMcKay @DrKarineTawagi @DrYukselUrun @yekeduz_emre @OncoAlert @urotoday @OncBrothers

Most Popular Users

Elon Musk 
@elonmusk
240.6M followers

Barack Obama 
@barackobama
119.2M followers

Donald J. Trump 
@realdonaldtrump
111.7M followers

Cristiano Ronaldo 
@cristiano
110.5M followers

Narendra Modi 
@narendramodi
107M followers

Rihanna 
@rihanna
97.6M followers

NASA 
@nasa
92.2M followers

Justin Bieber 
@justinbieber
90.9M followers

KATY PERRY 
@katyperry
87.6M followers

Taylor Swift 
@taylorswift13
81.4M followers

Lady Gaga 
@ladygaga
73M followers

Virat Kohli 
@imvkohli
69.8M followers

Kim Kardashian 
@kimkardashian
69.8M followers

YouTube 
@youtube
68.7M followers

Bill Gates 
@billgates
63.9M followers

Neymar Jr 
@neymarjr
62.5M followers

The Ellen Show
@theellenshow
62.4M followers

CNN 
@cnn
61.9M followers

X 
@x
60.8M followers

Selena Gomez 
@selenagomez
60.7M followers





